Saturday, February 01, 2025 3:46:04 PM
Kiwi, I think we are at the point where US revenues are no longer supporting international growth. With U.S. revenue at about $100M a year (annualized run-rate, based on where Q4 is likely coming in at), and cost of good sold at around $63M, that leaves us with $37M in U.S. Gross Profit Margin. Overall Operating Expenses are around $150M. Obviously, some of that is attributable to overseas operations (which they do not break out). So we are losing $75-100M a year on the U.S. operation alone.
Q3 annualized saw Amarin as a whole, losing $100M/year (run rate). Changes in A/R, Inventory, and add-backs due to stock-based comp helped minimize cash burn. But those items can't continue indefinitely (A/R and Inventory specifically). So very soon (probably starting in Q4), the cash is going to start burning quickly, assuming that revenues in Europe don't heat up exponentially (hint: they won't). We won't see anything from China, Italy, or anywhere else, other than UK, Spain, and a few of our RoW partners (Canada, etc.) contributing a few million. Revenues outside of U.S. in Q4 will likely be $5-7M more than Q3. After COGS, that leaves maybe $2-3M in Gross Profit on the incremental revenues. That's just not going to move the needle.
Bottom line, they have squeezed as much from the lemon as they are going to get on the expense side. And the only way out of this now is to grow revenues. This is probably why they have not initiated the buyback (and possibly won't - or maybe just a nominal amount as a show of faith). If they are burning $25M+ per quarter in cash, it's going to go quickly now. I am hoping the ER CC is going to be very revealing in terms of their plan.
Q3 annualized saw Amarin as a whole, losing $100M/year (run rate). Changes in A/R, Inventory, and add-backs due to stock-based comp helped minimize cash burn. But those items can't continue indefinitely (A/R and Inventory specifically). So very soon (probably starting in Q4), the cash is going to start burning quickly, assuming that revenues in Europe don't heat up exponentially (hint: they won't). We won't see anything from China, Italy, or anywhere else, other than UK, Spain, and a few of our RoW partners (Canada, etc.) contributing a few million. Revenues outside of U.S. in Q4 will likely be $5-7M more than Q3. After COGS, that leaves maybe $2-3M in Gross Profit on the incremental revenues. That's just not going to move the needle.
Bottom line, they have squeezed as much from the lemon as they are going to get on the expense side. And the only way out of this now is to grow revenues. This is probably why they have not initiated the buyback (and possibly won't - or maybe just a nominal amount as a show of faith). If they are burning $25M+ per quarter in cash, it's going to go quickly now. I am hoping the ER CC is going to be very revealing in terms of their plan.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
